RISPERDAL® CONSTA® (risperidone) Long Acting Injection

About Schizophrenia
Diagnosis of Schizophrenia
Living with Schizophrenia
Treating Schizophrenia
Importance of a Healthy
Lifestyle
Benefits of Regular Exercise
Benefits of Eating Healthy
About Relapse
Evolution of Treatment
About RISPERDAL CONSTA
Staying on Treatment
News Center
Resources
Frequently Asked Questions
También en Español
Full US Prescribing Information
Sitemap
Global Resources
Tell a friend
Privacy Policy
Legal Notice
Printer Friendly
 Text Size:  S | M |  L
 
 
 
    


Treating Schizophrenia

Medications
Psychosocial counselling
Support systems

Schizophrenia is best treated with a combination of medication, psychosocial counseling and a strong support system.

Medications

While schizophrenia cannot be cured, the symptoms can usually be controlled. With treatment, people with schizophrenia are able to function more effectively. They are able to work and socialize with family and friends.

Schizophrenia symptoms can be treated with antipsychotic medications. These medications reduce the symptoms of schizophrenia and help delay relapses. Conventional antipsychotic drugs, such as HALDOL ® (haloperidol), have been available since the mid-1950s. These drugs primarily block dopamine receptors and are effective in treating the "positive" symptoms of schizophrenia.

The newer antipsychotics (called atypical antipsychotics), block both serotonin and dopamine receptors, and are effective in treating both the "positive" and "negative" symptoms of schizophrenia.

RISPERDAL CONSTA (risperidone) Long-Acting injection is an atypical antipsychotic medication. Ask your doctor about RISPERDAL CONSTA Long-Acting injection.

NAMI, The Nation's Voice on Mental Illness, says that science has greatly expanded our understanding and treatment of severe mental illnesses.

Treatment works. In a 2001 survey, the National Mental Health Association (NMHA) asked consumers of mental health services to rate the severity of their symptoms before and after treatment. With a score of 10 equaling the most severe symptoms, the average consumer said the severity of symptoms before treatment was 8.5, while the severity after treatment was 3.6.

It is important to know that while treatment can help reduce and control many symptoms, some people will continue to experience symptoms throughout their lives.

<Back to Top>


Psychosocial counseling

Psychosocial counseling usually focuses on the patient’s social functioning. It involves regularly scheduled meetings between the patient and a mental health professional such as a psychiatrist, psychologist, psychiatric social worker or nurse. Patients are usually taught coping and problem-solving skills e.g. how to handle stress in everyday life. Psychosocial counseling can help.

<Back to Top>


Support Systems

Family and friends play an essential role in providing support, comfort and stability to a patient with schizophrenia. Patients can also get emotional support from other people with the illness. It is important for patients to learn that they are not the only one dealing with schizophrenia. Peer support groups, led by trained peer educators, provide an opportunity for patients suffering from schizophrenia to connect with one another. It gives them an opportunity to share their experiences and develop new friendships.

<Back to Top>


    
Patient Brochure
View and download
Patient Brochure RISPERDAL CONSTA patient education brochure. Click here.
Learn about Side Effects
Learn about Side Effects
Read to learn about the most common side effects when taking
RISPERDAL CONSTA.
Read more.

 


RISPERDAL® CONSTA® (risperidone) is used for the treatment of schizophrenia.

IMPORTANT SAFETY INFORMATION FOR RISPERDAL® CONSTA®

Elderly Patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk of death compared to placebo. RISPERDAL® CONSTA® (risperidone) is not approved for the treatment of patients with dementia-related psychosis.

Neuroleptic Malignant Syndrome (NMS) is a rare and potentially fatal side effect reported with RISPERDAL® CONSTA® and similar medicines. Call your doctor immediately if the person being treated develops symptoms such as high fever; stiff muscles; shaking; confusion; sweating; changes in pulse, heart rate, or blood pressure; or muscle pain and weakness. Treatment should be stopped if the person being treated has NMS.

Tardive Dyskinesia (TD) is a serious, sometimes permanent side effect reported with RISPERDAL® CONSTA® and similar medications. TD includes uncontrollable movements of the face, tongue, and other parts of the body. The risk of developing TD and the chance that it will become permanent is thought to increase with the length of therapy and the overall dose taken by the patient. This condition can develop after a brief period of therapy at low doses, although this is much less common. There is no known treatment for TD, but it may go away partially or completely if therapy is stopped.

High blood sugar and diabetes have been reported with RISPERDAL® CONSTA® and similar medications. If the person being treated has diabetes or risk factors such as being overweight or a family history of diabetes, blood sugar testing should be performed at the beginning and throughout treatment with RISPERDAL® CONSTA®. Complications of diabetes can be serious and even life threatening. If signs of high blood sugar or diabetes develop, such as being thirsty all the time, going to the bathroom a lot, or feeling weak or hungry, contact your doctor.

RISPERDAL® CONSTA® and similar medications can raise the blood levels of a hormone known as prolactin, causing a condition known as hyperprolactinemia. Blood levels of prolactin remain elevated with continued use. Some side effects seen with these medications include the absence of a menstrual period; breasts producing milk; the development of breasts by males; and the inability to achieve an erection. The connection between prolactin levels and side effects is unknown.

Some people taking RISPERDAL® CONSTA® may feel faint or lightheaded when they stand up or sit up too quickly. By standing up or sitting up slowly and following your healthcare professional's dosing instructions, this side effect can be reduced or it may go away over time.

RISPERDAL® CONSTA® may affect your alertness or driving ability; therefore, do not drive or operate machinery before talking to your healthcare professional.

RISPERDAL® CONSTA® should be used cautiously in people with a seizure disorder, who have had seizures in the past, or who have conditions that increase their risk for seizures.

Extrapyramidal Symptoms (EPS) are usually persistent movement disorders or muscle disturbances, such as restlessness, tremors, and muscle stiffness. If you observe any of these symptoms, talk to your healthcare professional.

Inform your healthcare professional if you become pregnant or intend to become pregnant during therapy with RISPERDAL® CONSTA®. Caution should be exercised when RISPERDAL® CONSTA® is administered to a nursing woman.

RISPERDAL® CONSTA® may make you more sensitive to heat. You may have trouble cooling off, or be more likely to become dehydrated, so take care when exercising or when doing things that make you warm.

Some medications interact with RISPERDAL® CONSTA®. Please inform your healthcare professional of any medications or supplements that you are taking. Avoid alcohol while on RISPERDAL® CONSTA®.

In a study of people taking RISPERDAL® CONSTA®, the most common side effects in the treatment of schizophrenia were headache, tremors, dizziness, restlessness, tiredness, constipation, indigestion, sleepiness, weight gain, pain in the limbs, and dry mouth.

If you have any questions about RISPERDAL® CONSTA® or your therapy, talk with your doctor.

For more information, read the Important Product Information by clicking here.

01CS1054




Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.

Home   Janssen.com   Site Map   Contact Us   

© Ortho-McNeil-Janssen Pharmaceuticals, Inc. 2003 – 2008. This site is published by Janssen®, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. which is solely responsible for its contents. This site is intended for visitors from the United States.
This page was last updated on: Oct 08 2007 at 14:47:02 EDT